Which has stronger earnings & valuation, ABEO or VOR?

Abeona Therapeutics has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abeona Therapeutics $5.82M 61.75 $71.18M -$1.09 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is ABEO or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Vor Biopharma N/A N/A N/A

Is AKTS or ABEO more profitable?

Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Abeona Therapeutics N/A -41.69% -30.36%

Does the media prefer AKTS or ABEO?

In the previous week, Aktis Oncology had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Aktis Oncology and 7 mentions for Abeona Therapeutics. Aktis Oncology's average media sentiment score of 0.54 beat Abeona Therapeutics' score of -0.08 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Abeona Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVAX or ABEO?

In the previous week, Novavax had 8 more articles in the media than Abeona Therapeutics. MarketBeat recorded 15 mentions for Novavax and 7 mentions for Abeona Therapeutics. Novavax's average media sentiment score of 0.19 beat Abeona Therapeutics' score of -0.08 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Abeona Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ABEO or GLUE?

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 7 mentions for Abeona Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.49 beat Abeona Therapeutics' score of -0.08 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monte Rosa Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ABEO or CGEM more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media refer more to ABEO or CGEM?

In the previous week, Abeona Therapeutics had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 7 mentions for Abeona Therapeutics and 6 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.80 beat Abeona Therapeutics' score of -0.08 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abeona Therapeutics (ABEO) Competitors

$6.28 +0.23 (+3.71%)

As of 03:35 PM Eastern

Compare

ABEO vs. VOR, AKTS, NVAX, GLUE, and CGEM

Should you buy Abeona Therapeutics stock or one of its competitors? Abeona Therapeutics's main competitors and comparable companies include Vor Biopharma (VOR), Aktis Oncology (AKTS), Novavax (NVAX), Monte Rosa Therapeutics (GLUE), and Cullinan Therapeutics (CGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abeona Therapeutics compare to Vor Biopharma?

Abeona Therapeutics (NASDAQ:ABEO) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Abeona Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

In the previous week, Abeona Therapeutics had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 7 mentions for Abeona Therapeutics and 0 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 beat Abeona Therapeutics' score of -0.08 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Abeona Therapeutics	Neutral
Vor Biopharma	Neutral

Abeona Therapeutics currently has a consensus target price of $19.33, suggesting a potential upside of 207.61%. Vor Biopharma has a consensus target price of $43.38, suggesting a potential upside of 80.28%. Given Abeona Therapeutics' higher possible upside, research analysts clearly believe Abeona Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Vor Biopharma's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Vor Biopharma	N/A	N/A	N/A

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abeona Therapeutics has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	61.75	$71.18M	-$1.09	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Summary

Vor Biopharma beats Abeona Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Abeona Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Abeona Therapeutics	N/A	-41.69%	-30.36%

Abeona Therapeutics has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	220.59	-$63.73M	-$0.82	N/A
Abeona Therapeutics	$5.82M	61.75	$71.18M	-$1.09	N/A

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aktis Oncology currently has a consensus price target of $35.00, suggesting a potential upside of 31.20%. Abeona Therapeutics has a consensus price target of $19.33, suggesting a potential upside of 207.61%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Aktis Oncology had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Aktis Oncology and 7 mentions for Abeona Therapeutics. Aktis Oncology's average media sentiment score of 0.54 beat Abeona Therapeutics' score of -0.08 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Abeona Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aktis Oncology beats Abeona Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

In the previous week, Novavax had 8 more articles in the media than Abeona Therapeutics. MarketBeat recorded 15 mentions for Novavax and 7 mentions for Abeona Therapeutics. Novavax's average media sentiment score of 0.19 beat Abeona Therapeutics' score of -0.08 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Abeona Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novavax has higher revenue and earnings than Abeona Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	3.76	$440.30M	-$1.52	N/A
Abeona Therapeutics	$5.82M	61.75	$71.18M	-$1.09	N/A

Novavax currently has a consensus price target of $14.00, suggesting a potential upside of 48.26%. Abeona Therapeutics has a consensus price target of $19.33, suggesting a potential upside of 207.61%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

53.0% of Novavax shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novavax has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Abeona Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Summary

Novavax beats Abeona Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Monte Rosa Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Abeona Therapeutics currently has a consensus target price of $19.33, indicating a potential upside of 207.61%. Monte Rosa Therapeutics has a consensus target price of $28.50, indicating a potential upside of 96.38%. Given Abeona Therapeutics' higher possible upside, equities analysts clearly believe Abeona Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Abeona Therapeutics has higher earnings, but lower revenue than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	61.75	$71.18M	-$1.09	N/A
Monte Rosa Therapeutics	$28.73M	43.10	-$38.63M	-$1.76	N/A

Abeona Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Abeona Therapeutics' return on equity of -41.69% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 7 mentions for Abeona Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.49 beat Abeona Therapeutics' score of -0.08 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Abeona Therapeutics beats Monte Rosa Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Abeona Therapeutics compare to Cullinan Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Abeona Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	61.75	$71.18M	-$1.09	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Abeona Therapeutics' return on equity of -41.69% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

In the previous week, Abeona Therapeutics had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 7 mentions for Abeona Therapeutics and 6 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.80 beat Abeona Therapeutics' score of -0.08 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abeona Therapeutics currently has a consensus target price of $19.33, suggesting a potential upside of 207.61%. Cullinan Therapeutics has a consensus target price of $32.86, suggesting a potential upside of 43.20%. Given Abeona Therapeutics' higher possible upside, equities analysts plainly believe Abeona Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Abeona Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Summary

Abeona Therapeutics beats Cullinan Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$359.95M	$4.04B	$7.32B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-5.78	11.72	271.20	24.17
Price / Sales	61.75	1,431.37	696.57	128.56
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	2.14	17.52	11.33	6.51
Net Income	$71.18M	-$22.72M	$3.46B	$347.63M
7 Day Performance	2.03%	4.50%	3.12%	1.53%
1 Month Performance	3.88%	11.99%	8.67%	5.17%
1 Year Performance	-10.34%	60.24%	27.37%	17.69%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	2.1795 of 5 stars	$6.29 +3.7%	$19.33 +207.6%	-16.2%	$359.95M	$5.82M	N/A	90	Analyst Revision
VOR Vor Biopharma	2.0281 of 5 stars	$23.01 -0.1%	$43.38 +88.5%	-47.7%	$1.36B	N/A	N/A	140
AKTS Aktis Oncology	2.9316 of 5 stars	$24.72 -0.8%	$34.60 +40.0%	N/A	$1.33B	$6.50M	N/A	76	Gap Up
NVAX Novavax	1.673 of 5 stars	$8.07 +0.2%	$13.00 +61.1%	+13.0%	$1.33B	$1.12B	N/A	1,990	Gap Up
GLUE Monte Rosa Therapeutics	2.9377 of 5 stars	$15.38 -0.8%	$28.50 +85.3%	+185.7%	$1.32B	$123.67M	N/A	90	News Coverage Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. VOR, AKTS, NVAX, GLUE, and CGEM

How does Abeona Therapeutics compare to Vor Biopharma?

Summary

How does Abeona Therapeutics compare to Aktis Oncology?

Summary

How does Abeona Therapeutics compare to Novavax?

Summary

How does Abeona Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does Abeona Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. VOR, AKTS, NVAX, GLUE, and CGEM

How does Abeona Therapeutics compare to Vor Biopharma?

Which has more volatility & risk, ABEO or VOR?

Does the media favor ABEO or VOR?

Do analysts prefer ABEO or VOR?

Is ABEO or VOR more profitable?

Do institutionals and insiders have more ownership in ABEO or VOR?

Which has stronger earnings & valuation, ABEO or VOR?

Summary

How does Abeona Therapeutics compare to Aktis Oncology?

Is AKTS or ABEO more profitable?

Which has higher earnings & valuation, AKTS or ABEO?

Do institutionals and insiders hold more shares of AKTS or ABEO?

Do analysts rate AKTS or ABEO?

Does the media prefer AKTS or ABEO?

Summary

How does Abeona Therapeutics compare to Novavax?

Does the media favor NVAX or ABEO?

Which has stronger valuation and earnings, NVAX or ABEO?

Do analysts recommend NVAX or ABEO?

Do institutionals and insiders hold more shares of NVAX or ABEO?

Which has more volatility and risk, NVAX or ABEO?

Is NVAX or ABEO more profitable?

Summary

How does Abeona Therapeutics compare to Monte Rosa Therapeutics?

Do analysts recommend ABEO or GLUE?

Which has more risk & volatility, ABEO or GLUE?

Do insiders and institutionals have more ownership in ABEO or GLUE?

Which has better valuation & earnings, ABEO or GLUE?

Is ABEO or GLUE more profitable?

Does the media prefer ABEO or GLUE?

Summary

How does Abeona Therapeutics compare to Cullinan Therapeutics?

Which has better earnings and valuation, ABEO or CGEM?

Do institutionals and insiders hold more shares of ABEO or CGEM?

Is ABEO or CGEM more profitable?

Does the media refer more to ABEO or CGEM?

Do analysts prefer ABEO or CGEM?

Which has more volatility & risk, ABEO or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools